RanBP2 is identified as a potential therapeutic target to suppress ANE1-driven cytokine storms and combat hyperinflammation in response to viral infections.
RanBP2 is highlighted as a potential therapeutic target to suppress ANE1-driven cytokine storms and hyperinflammation in response to viral infections.
Ran Binding Protein 2 (RanBP2 or Nucleoporin358) is one of the main components of the cytoplasmic filaments of the nuclear pore complex. Mutations in the RANBP2 gene are associated with acute necrotizing encephalopathy type 1 (ANE1), a rare condition where patients experience a sharp rise in cytokine production in response to viral infection and undergo hyperinflammation, seizures, coma, and a high rate of mortality. Despite this, it remains unclear howRanBP2 and its ANE1-associated mutations contribute to pathology. Mounting evidence has shown that RanBP2 interacts with distinct viruses to regulate viral infection. In addition, RanBP2 may regulate innate immune response pathways. This review summarizes recent advances in our understanding of how mutations in RANBP2 contribute to ANE1 and discusses how RanBP2 interacts with distinct viruses and affects viral infection. Recent findings indicate that RanBP2 might be an important therapeutic target, not only in the suppression of ANE1-driven cytokine storms, but also to combat hyperinflammation in response to viral infections.
Jiang et al. (Thu,) conducted a review in Acute Necrotizing Encephalopathy Type 1 (ANE1) and viral infection. RanBP2/Nup358 was evaluated. RanBP2 is identified as a potential therapeutic target to suppress ANE1-driven cytokine storms and combat hyperinflammation in response to viral infections.